Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma With Joseph Kalis, PharmD, BCOP, and Eric Cannon, PharmD, FAMCP

Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification (Kumar et al, 2022). Clinicians are challenged with leveraging the best available evidence and meeting individual care needs in diverse patient populations across different settings, and gaps remain in promoting collaboration between the multidisciplinary team and managed care professionals in their goal of providing value-based treatment and survivorship care plans. In this continuing pharmacy education (CPE)–approved activity,  Joseph A. Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, and Eric Cannon, PharmD, FAMCP, Chief Pharmacy Benefits Officer at SelectHealth, will explore strategies for aligning treatment goals and value-based care for patients with newly diagnosed multiple myeloma.  



Related Articles

Responses

Your email address will not be published. Required fields are marked *